K-ras gene plays an important role in regulating cell growth and differentiation. Certain tumors, such as colorectal carcinoma, lung carcinoma, pancreatic carcinoma, etc., relate with K-ras gene mutation.The mutation rate of K-ras gene was reported to be 20–40% in colorectal carcinoma, 10–17% in lung carcinoma and 59% in pancreatic carcinoma.It was also reported that about 95% K-ras mutations were related with the mutations of codons 12–13.Of note, the US food and drug administration (FDA) advised in 2009 that K-ras gene mutations required to be examined before metastatic colorectal carcinoma was treated by targeted drugs such as Erbitux and Panitumumab.
Therefore, it is important that K-ras gene mutations in clinical tumor samples be identified promptly and accurately.
Mylab Discovery Solutions provides real time PCR genotyping assay for detection of seven common mutations in codon 12 and 13 of KRAS gene (Gly12Ala, Gly12Asp, ly12Arg, Gly12Cys, Gly12Ser, Gly12Val, and Gly13Asp). Mutation specific amplification is achieved by mutation specific primers. Taq DNA polymerase is extremely effective at distinguishing between a match and a mismatch at the 3′-end of a PCR primer. Specific mutated sequences can be selectively amplified, even in the presence of wild type sequences. Detection of amplification is performed using Taqman probe.
A combination of robust reagents for DNA extraction from clinical samples and validated primers, hydrolysis probe as well as hot start Taq polymerase for genotyping ensures that kit leads to highly specific and sensitive results in short time.
| # | Product | Cat. No. | Reaction size/kit |
|---|---|---|---|
| 1 | Oncoscreen KRAS Mutation Detection kit (codon 12 & 13) | OKDE25 | 25 |
| 2 | Oncoscreen KRAS Mutation Detection kit (codon 12 & 13) | OKDE50 | 50 |
